Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Journal article (3)
Language
- English (3)
Keywords
- bone disease (2)
- multiple myeloma (2)
- positron emission tomography (2)
- CXCR4 (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- PRRT (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{18}\)F-FDG PET/CT (1)
- autologous transplantation (1)
- cancer (1)
- cells (1)
- chemokine receptor (1)
- esophagogastric junction (1)
- experience (1)
- imaging techniques (1)
- in vivo imaging (1)
- involvement (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- molecular imaging (1)
- peptide receptor (1)
- radionuclide therapy (1)
- sarcoidosis (1)
- somatostatin receptors (1)
- stem-cell transplantation (1)
- survival (1)
- treatment response (1)
Institute
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (3) (remove)
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods:
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results:
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion:
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.